A live archive of receipt-bound excerpts from company earnings calls. No generated thesis, no recommendation — just the recorded language, its source coordinates, and a direct path into the ticker dossier or live Terminal.来自公司财报电话会的可追溯摘录档案。没有生成式投资结论，也没有推荐——只有原始表述、来源坐标，以及进入个股档案或实时终端的直接入口。
Start free in Terminal免费开始使用终端649 verified call records份已核验电话会记录 · 7788 exact facts条精确事实 · 2026-10-26 → 2026-11-01
Browse the full archive page by page. Search on this page by ticker, period, category, or speaker; every card preview is a verbatim call excerpt.分页浏览完整档案。在本页按代码、期间、分类或发言人搜索；每张卡片预览均为电话会原文摘录。
Showing records 481–576 of 6702.显示第 481–576 条，共 6702 条。
“Key assumptions in our revised guidance include shopping center same property NOI growth of 5%-6%, investment volume including commercial loans and structured investments of approximately $472 million, up from our prior range of $300 million-$400 million.”
“We are now targeting Adjusted EBITDA, excluding the non-cash impact of metal price lag, in the range of $1.03 billion to $1.06 billion, and free cash flow in excess of $300 million.”
“For the full year, we expect ROIC of approximately 25% and free cash flow margin of approximately 15%.”
“Together, these drivers resulted in 8% core sales growth, strong operating leverage, record margins, record earnings, and a record backlog while reinforcing our confidence in the outlook for both 2026 and 2027.”
“Net interest margin increased five basis points from the prior quarter and 13 basis points from the year-ago quarter to 3.62%.”
“Now looking ahead, we expect continued grain volume growth through the end of the year and into early 2027, supported by healthy supply and demand fundamentals, combined with our diverse market reach.”
“Book-to-bill was solidly above one, and total bookings grew 126% year-over-year, driven by a 318% increase in systems bookings and 36% growth in recurring bookings.”
“Operating income increased by 35.4% to $41 million year-over-year, demonstrating strong operating leverage as we continue to balance expense discipline with targeted investment in areas of our business that will drive future growth.”
“With respect to profitability guidance for 2026, we now expect non-GAAP adjusted diluted earnings per share in the range of $4.54-$4.61, compared to our prior guidance range of $4.48-$4.60.”
“For Q4, we anticipate cost of sales to be around 30.5%, primarily due to the impact of our Smoked Brisket limited time offer.”
“That's one of the things that we have very clear examples in our capital sales results in the third quarter, as well as our capital sales funnel that we expect in Q4 and for the duration of 2027, where it is these new sites that have realized, hey, I probably need ClearPoint to participate in some of these existing studies, and it's no longer just the functional neurosurgeon reaching out to ClearPoint.”
“We delivered this margin improvement despite some early-stage headwinds from the acquisitions we completed this year, which we estimated reduced segment margin by approximately 20 basis points in the quarter.”
“As a result, since the end of 2023, we've expanded our NAST operating margin by over 1,500 basis points and achieved our mid-cycle target of a 40% operating margin, and we've done it despite facing headwinds from the overall market.”
“Obviously, you see it in our gross profit dollar growth at 15% year-over-year and strong gross profit margins.”
“Finally, based on the company's financial results through September 30th, 2026, we expect to finish the year at or slightly above the high end of our full year 2026 adjusted EPS guidance discussed in our second quarter 2026 earnings press release, dated July 28th, 2026.”
“For the fourth quarter 2026, we expect the most significant driver of our adjusted home building gross margin to continue to be incentives needed to generate an acceptable sales pace, which, as Rob noted earlier, we currently expect to be 200-250 basis points higher than third quarter 2026 levels.”
“The three office developments are 70% pre-leased, and the aggregate pipeline will deliver meaningful external growth over the longer term.”
“We have an impactful cadence of future growth catalysts anticipated in 2027 and 2028 that we expect to drive meaningful improvement to our growth profile in 2028 and beyond.”
“We have a good demand in terms of price, return, and risk, we are most likely going to grow.”
“If that means that the pipeline or the loan book growth has to slow a little bit for the quarter, as Andrew said, it's grown $700 million in the year.”
“Our top-line performance, combined with strong merchandise margin expansion and disciplined expense management, drove a 26% increase in second-quarter earnings per diluted share to $1.73, exceeding the high end of our guidance range by $0.08.”
“As a reminder, from 2026 through 2030, we are targeting double-digit annual EPS growth driven by total organic revenue growth of 4%-6% annually, with potential upside from viral events and new product launches such as our Agents for Good catalog and adjusted EBITDA growth of 6%-8% annually while expanding our adjusted EBITDA margin to 40%+.”
“At the midpoint, our guidance implies an adjusted EBITDA margin of approximately 20.3%, which is about 130 basis points above our full-year 2026 outlook provided at Investor Day.”
“But I would say specifically for IET, as we move into 2028, that combination of additional capacity coming online, the backlog we have and the visibility we have to book-to-bill in 2027 should support an acceleration in growth and drive further margin expansion.”
“SYFOVRE revenue was $191 million, up 27% year-over-year, driven by continued commercial injection volume growth, which was up 18% year-over-year and 7% quarter-over-quarter.”
“Given the acceleration we expect to maintain throughout the back half, this gives us the confidence to raise our outlook for the fourth quarter and the full year as we now expect 2026 revenue to exceed $3 billion.”
“Total core loans increased 8% with strong production across multiple loan categories, while loans held for sale decreased 45%, reflecting the impact of our targeted loan sales.”
“We now expect full year 2026 revenue growth of at least 29%, or revenue of at least $290 million, including at least $7 million of revenue from BioCircuit.”
“On a year-over-year basis, BMP revenue grew 3.6% organically, ahead of our expectation, despite 150 basis point headwind from the unusual customers' ordering and shipment patterns that we have discussed on prior calls.”
“Can you talk more about how you've kind of addressed those and to the extent that entailed higher pricing for those components, what that might mean for margin, that's free cash flow into 2027, and if that impacts the targets you gave at Investor Day for gross profit positive?”
“Turning to our outlook, and obviously assuming the continuation of current market conditions as well as constant exchange rates, for the fourth quarter, we expect sales in the range of $10.3 billion-$10.5 billion, and adjusted diluted EPS in the range of $0.81-$0.83.”
“On a standalone basis, excluding cash and other transaction expenses from the impact of the USI acquisition, we remain confident in our ability to deliver our previously communicated full year 2026 guidance across organic revenue, margin expansion, EPS, and free cash flow growth.”
“While we expect our cost per unit to decline over time, the benefit will flow through gradually, and gross margin may vary from quarter to quarter based on sales mix and the timing and volume of partner shipments.”
“For the fourth quarter of 2026, we expect revenue of $139.7-$141.2 million, representing growth of 15.6%-16.9%, and Adjusted EBITDA of $30-$31 million or a 21.7% margin at the midpoint.”
“Assuming no circumstances occur beyond our control that could impact our business, for Q4 2026, we expect worldwide revenues to be in the range of $1 billion-$1,020,000,000.”
“Reflecting our performance and positive outlook, we are raising our full year 2026 earnings guidance to $20.70 per share, excluding any additional gains on asset sales in the fourth quarter.”
“As a result, we now have confidence to expect full-year operating earnings to be at or above the high end of our recently increased 2026 guidance range of $6.25-$6.55 per share.”
“Putting it all together, we are pleased to increase our fiscal 2027 consolidated revenue outlook to about 6% growth while maintaining our forecast for adjusted EBIT margin expansion of 70 to 90 basis points.”
“Despite the top-line challenge, our disciplined execution is still expected to result in EBITDA margin of roughly 23.2% or 100 basis point expansion versus the prior year, driven by productivity and price more than offsetting inflation as well as investments for growth.”
“With WVE-006, which targets the underlying causes of AATD, we have generated a growing body of data supporting its potential as a new standard of care for individuals living with Alpha-1 by restoring an MZ-like phenotype, which has a low risk of lung and liver disease.”
“Turning to Slide 20, we are updating our full-year guidance across organic net sales, ongoing EBIT, and ongoing EBIT margin to reflect the current pace of our margin recovery.”
“Our third quarter adjusted operating margin of 4.1% reflects over 200 basis points of operational headwinds previously mentioned.”
“For full year 2026, we now expect ASM growth of approximately 5% year-over-year, an EBITDAR margin of around 21%, primarily driven by higher fuel price assumptions and CAPEX of around $350 million.”
“Our issuing, acceptance, and risk and security portfolios collectively grew more than 20% in constant dollars this year, a growth rate we believe is sustainable in 2027 for two primary reasons: the underlying drivers of revenue and demand from clients.”
“With that backdrop, we expect fourth quarter revenue in International to be up approximately 7% and operating margin of approximately 20%.”
“We continue to see a path to our target of 20% gross margin at $4 billion of revenue, driven by higher volume utilization, a growing mix of higher value engineered products, increased vertical integration, and more production in lower cost regions.”
“For Q4 2026, we expect year-over-year revenue growth.”
“Revenue grew in 2020 despite COVID-impacted conditions, and we grew 5% in 2023 despite inflation-driven profitability pressures across the insurance industry.”
“Since September 2025, we've originated $2.3 billion of loan investments, representing nearly 45% of our current loan portfolio and contributing to a 36% year-over-year growth in net earning assets while maintaining a disciplined approach to underwriting, portfolio construction, and risk management.”
“For the full year, we expect gross VOI sales in the range of $2.625 billion-$2.675 billion, volume per guest of $3,325-$3,375, and EBITDA of $1.07 billion-$1.085 billion.”
“Domestic Coke increased by $7.1 million, primarily driven by a change in the mix of contract and spot coke sales and favorable coal-to-coke yields, partially offset by lower coke sales volumes due to Haverhill I shutdown.”
“Given that the preliminary rent growth for 2027 is higher, should we expect kind of similar highish numbers, going forward in the MH business?”
“The strong demand environment, combined with disciplined expense management, drove substantial operating leverage, with non-GAAP operating profit up 33% sequentially to $2.1 billion, representing 50.7% of revenue.”
“For the fourth quarter, we expect revenue of $942 million-$972 million, adjusted operating income of $185 million-$192 million, adjusted operating margin of 19.6%-19.8%, adjusted net income of $140 million-$145 million, and adjusted earnings per share of $0.95-$0.99.”
“Our updated guidance assumes high single-digit billed issuance growth for the full year, reflecting our continued expectations for $250 billion-$300 billion in hyperscaler issuance.”
“For Q4 2026, on a segment level, we expect approximately $785 million of revenue in lending, $550 million of revenue in financial services, $90 million of revenue in technology platform, and corporate revenue in line with the third quarter.”
“Adjusted operating income was CAD 5.3 million, an increase of CAD 0.2 million or 4.7%, as promotional and product mix efficiencies and increased data revenue more than offset the impact of higher asset impairment reversals in the prior year period.”
“As to the first quarter of 2027, we expect net sales to decline between 19% and 22%, driven by current sales momentum and the impact of our price increase.”
“While these commodity market-driven challenges primarily impacted our upstream fresh pork and hog production segments, which reset our full-year outlook, our packaged meat segment demonstrated its resilience with year-over-year volume, profit, and margin expansion.”
“In other words, should we just assume flat SG&A and R&D and maybe a 50% incremental type of EBITDA margin on incremental sales going forward?”
“In addition, gene therapy demand grew on an absolute basis and north of 25%, excluding that gene therapy headwind.”
“Since the last earnings call, booking volumes have increased in the mid-teens year-over-year, and bookings for 2027 sailings up in the high teens, demonstrating strong demand as we continue to build a strong base of business for 2027.”
“With respect to margins, expenses, and EPS, we are adjusting our guidance based on higher sales in addition to changes from the impact of tariffs and projected performance-based compensation.”
“Consolidated non-GAAP gross margin was 50.3%, improving 100 basis points sequentially on higher revenue and improved operating leverage, while declining 230 basis points year over year, primarily due to product and customer mix.”
“The combination of stronger transaction margin performance and lower operating expenses resulted in non-GAAP earnings per share growth of 8% to $1.45 above our guidance.”
“Total revenue margin for the fourth quarter increased 20 basis points to 17.6% of total revenue, compared to the same period last year.”
“We also expect to maintain our strong profitability, with Pool delivering approximately 30% return on sales for full year 2027, while continuing to invest in innovation, our brand, and our industry-leading position.”
“On an operational basis, excluding tariff refunds, we expect margin expansion of approximately 165-170 basis points compared with our prior outlook of 145-170 basis points.”
“For the full year, we expect cost of goods sold to be approximately 12% of revenue, including the $10 million manufacturing inventory impairments recorded in Q2 and Q3, corresponding to a gross margin of around 88%.”
“Operating margin increased 420 basis points year-over-year to 16.4%, exceeding the top end of our targeted range.”
“Given the strength of our pipeline, we recently increased our full-year gross acquisition guidance to $600 million-$700 million.”
“As Brent noted in his remarks, for the third quarter in a row, we are increasing and narrowing our 2026 annual core FFO guidance to a range of $1.55-$1.57 per diluted share, an increase of $0.06 per share at the midpoint when compared to our original 2026 guidance and equating to an earnings growth rate of over 10%.”
“Outlook for 2026, I mentioned the continued growth in the fourth quarter, and we will finish within the range that we had forecasted, the 3%-5% we had given previously.”
“We expect non-GAAP gross margin of 59%, ± 50 basis points, driven by higher revenue and manufacturing utilizations.”
“There were some unusual items during the quarter, including the favorable resolution of a portion of the borrower exposure, but the broader story is the strength of the underlying franchise, record earnings, continued margin expansion, strong operating leverage, and tangible book value of $22.35 per share.”
“As we look ahead for the rest of 2026, we continue to focus on organic growth initiatives, further optimizing our operations, and driving improved financial performance, expanding our financial center network, and serving our core customers and communities.”
“I think the silver lining here, though, Bill, is we have guided you to steel mills earnings having relatively flat quarter-over-quarter and really that is just for all the obvious reasons, we are going to see some volume softness due to seasonality and the outages, but stronger pricing outlook sort of neutralizes that impact.”
“We expect further sequential margin improvement in Q4, although I would remind investors that fourth quarter margins have historically benefited from the seasonality of certain revenues and should not automatically be treated as a new quarterly run rate.”
“Additionally, capital expenditure guidance for this year has been increased to $680 million-$705 million, compared with $615 million-$665 million previously, with the increase primarily attributable to higher customer reimbursable capital expenditures, which is now expected to total roughly $65 million for this year as compared to $25 million previously.”
“As a result, we now expect total 2026 revenue to exceed our prior outlook of approximately $500,000.”
“For the fourth quarter, we expect AFFO of approximately $0.82-$0.84 per share, and year-end AFFO annual run rate above the $3.30 per share guidance provided on our year-end 2025 earnings call.”
“With all that said, and acknowledging the volatile macro environment, given our strong year-to-date performance and solid pipeline, we are increasing our RPO outlook to 21% year-over-year growth, up from our prior target range of 18%-20% growth.”
“Operating leverage, combined with the restructuring of our credit facility earlier this year, which extends the maturity of our debt to 2031 and provides us with access to an additional $20 million in undrawn capital subject to certain revenue milestones, has left us well-positioned to continue our positive trajectory.”
“Transportation logistics segment revenue was up 18% year-over-year on a 16% increase in revenue per load and a 2% increase in volume compared to the 2025 second quarter.”
“To reiterate some of those highlights, we delivered solid organic growth, further advanced our advisor experience through investments in our service organization, drove improved operating leverage through ongoing efficiency gains and better monetization of the value we deliver to clients, progressed our preparations to onboard Commonwealth in mid-November, and executed on our capital allocation strategy where we remained active with our Liquidity & Succession capability and returned approximately $300 million to shareholders through share repurchases.”
“Despite this inflationary pressure, which we expect to continue throughout the remainder of our fiscal year, we now expect fiscal year 2027 Non-GAAP operating income margin to be at the high end of our long-term 15%-18% range, even excluding the $61 million tariff refunds from last quarter.”
“We expect Americas Welding margin to perform in a 20%-21% EBIT margin range for the fourth quarter, given sales momentum and improved price cost performance.”
“B, just maybe taking it broader, as you look out to 2027 across the business globally, can you just discuss the challenge you see from cycling some of these tougher comparisons on the unit case side and how you think about the system's ability to continue to sustain volume growth going forward?”
“While we believe that ARCALYST has a lot of growth left in it to address the recurrent pericarditis opportunity, with KPL-387, patients did tell us that around 75% of them would prefer the KPL-387 target profile being a monthly liquid formulation, potentially auto injector over current commercial or other investigational therapies.”
“While some of these products are not expected to contribute significant revenue in 2026, their release shows that the super cycle is progressing as planned, and we expect the bigger growth opportunity to come in 2027 and beyond as we move toward full launches and wider adoption.”
“The $23 billion backlog we have now accumulated over the past year, that really provides us very clear visibility into the growth for 2027 and is fully embedded in how we have outlooked the 11%-12% organic revenue growth for the years.”
“On a sequential quarter basis, net revenue growth was 4%, while adjusted operating expenses declined by 1%, generating over 500 basis points of positive operating leverage and a 320 basis point operating margin improvement in the third quarter, with operating margin improving to 40.7%, the highest level since 2021.”
“Maybe more importantly, as we go into 2027, not so much the backlog, but just the underlying momentum that we are seeing in these businesses, the feedback we are getting from customers, the new products that are coming through at significantly higher margins now, as Chris said, at a 3%+ CBI contribution.”
“So maybe the customer would do $10 million or $11 million, $10 million deals rather than one $100 million deal, just as an example, where you are buying with the area under the curve being the same or greater, and certainly probably greater from a margin perspective, is really what it looks like.”
“This backlog adjustment has no impact on historical financial results, 2026 guidance, net new bookings, or next 12 months revenue from backlog customers.”
“Firm AI, now with Celeste as the re-architected core platform across our growth, compliance, and profitability offerings, represented more than 40% of net new bookings in FQ1, up from over 20% last quarter.”
Try a ticker, period, category, or a call speaker.请尝试代码、期间、分类或电话会发言人。
This is a transcript-only, historically incomplete publication. Releases, filings, slides, consensus and price reaction are visibly marked as not joined; lower-evidence packets remain held instead of being inferred.这是仅基于电话会文本且历史覆盖尚不完整的发布。新闻稿、披露文件、演示材料、一致预期和股价反应均明确标注为未接入；证据不足的数据包会被暂缓，而非由推断补齐。